Merck & Co.
NYSE:MRKPharmaRahway, NJ, United States · Est. 1891 · 69,000 employees
Global healthcare company delivering innovative health solutions.
113
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
176
Indications↗
Distinct diseases across all programs
2,728
Clinical Trials↗
All sponsored trials (all statuses)
18
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
113 drugs in development
Approved3
Phase 364
Phase 251
Phase 126
Preclinical28
By Therapeutic Area
top 6
Oncology
6642%
Immunology
1912%
Infectious Disease
1811%
Metabolic & Endocrine
74%
Neurology
64%
Cardiovascular
53%
R&D Momentum
100/100
Pipeline Velocity
84/100
Trial Completion Rate
83/100
Pipeline Concentration
23/100
Pipeline Freshness
72/100
Strategic Signals
- ↗Active in Rare Disease but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Aug 28, 2026
Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Aug 28, 2026
Recruiting
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)
Aug 28, 2026
Active, not recruiting
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
Aug 27, 2026
Completed
A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)
Aug 27, 2026
Active, not recruiting
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer
Aug 27, 2026
Active, not recruiting
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer
Aug 27, 2026
Recruiting
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
Aug 27, 2026
Completed
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C
Aug 27, 2026
Completed
A Clinical Trial to Study the Effect of a Single Dose of MK-8527 on the Pharmacokinetics of Methadone
Aug 27, 2026
Recruiting
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
Aug 27, 2026
Recruiting
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)
Details
Company Info
Company Overview
$290.0B
Mkt Cap
$60.1B
Revenue
$7.4B
Cash
CEORobert Davis
Founded1891
Employees69,000
HQRahway, NJ, United States
ExchangeNYSE:MRK
Websitemerck.com
LinkedInCompany Page
Therapeutic Focus
OncologyInfectious DiseaseOtherMusculoskeletalRespiratoryPsychiatryCardiovascularNeurologyImmunologyNephrologyOphthalmologyHematologyGastroenterologyDermatologyMetabolic & EndocrineRare Disease
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(5 drugs)
—
—
—
5
—
Cardiovascular(5 drugs)
Dermatology(1 drug)
—
—
1
—
—
Dermatology(1 drug)
Gastroenterology(3 drugs)
—
2
1
—
—
Gastroenterology(3 drugs)
Hematology(1 drug)
—
—
1
—
—
Hematology(1 drug)
Immunology(19 drugs)
—
2
7
9
1
Immunology(19 drugs)
Infectious Disease(18 drugs)
4
—
8
8
—
Infectious Disease(18 drugs)
Metabolic & Endocrine(7 drugs)
1
3
1
4
—
Metabolic & Endocrine(7 drugs)
Musculoskeletal(1 drug)
—
—
1
—
—
Musculoskeletal(1 drug)
Nephrology(3 drugs)
—
3
—
—
—
Nephrology(3 drugs)
Neurology(6 drugs)
—
1
3
2
1
Neurology(6 drugs)
Oncology(66 drugs)
22
19
40
37
1
Oncology(66 drugs)
Psychiatry(1 drug)
—
—
—
1
—
Psychiatry(1 drug)
Rare Disease(2 drugs)
—
—
1
1
—
Rare Disease(2 drugs)
Respiratory(3 drugs)
—
1
2
—
—
Respiratory(3 drugs)
Unknown / Other(22 drugs)
3
4
10
7
1
Unknown / Other(22 drugs)
Regulatory
Regulatory Timeline
19822 events
FDAJan 1
Guanidine Hydrochloride — GUANIDINE HYDROCHLORIDE
Application NDA001546 (NDA)
FDAJan 1
Aminohippurate Sodium — AMINOHIPPURATE SODIUM
Application NDA005619 (NDA)
20081 event
FDAMay 20
Entereg — ENTEREG
Application NDA021775 (NDA)
20111 event
FDAMay 27
Dificlir — DIFICID
Application NDA201699 (NDA)
20144 events
FDASep 4
Keytruda — Keytruda
Application 125514 (BLA)
FDASep 4
Keytruda — KEYTRUDA
Application BLA125514 (BLA)
FDAJun 20
Sivextro — SIVEXTRO
Application NDA205435 (NDA)
FDAJun 20
Sivextro — SIVEXTRO
Application NDA205436 (NDA)
20161 event
FDAOct 21
ZINPLAVA — ZINPLAVA
Application BLA761046 (BLA)
20201 event
FDAJan 24
Dificlir — DIFICID
Application NDA213138 (NDA)
20241 event
FDAMar 26
Winrevair — WINREVAIR
Application BLA761363 (BLA)
20251 event
FDAJun 9
ENFLONSIA — ENFLONSIA
Application BLA761432 (BLA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)